Atherosclerotic renovascular disease (ARVD) reduces tissue perfusion and eventually leads
to loss of kidney function with limited therapeutic options. Here we describe results of Phase …

Atherosclerotic renovascular disease (RVD) reduces renal blood flow (RBF) and GFR and
accelerates poststenotic kidney (STK) tissue injury. Preclinical studies indicate that …

BACKGROUND: Mesenchymal stem cells (MSCs) hold promise for the treatment of renal
disease. While MSCs have been shown to accelerate recovery and prevent acute renal …

Bone marrow–derived cells contribute to glomerular cell turnover and repair, but the cell
types involved are unknown. Whether rat mesenchymal stem cells (MSC) can accelerate …

Introduction Studies have shown that stem cells exert their therapeutic effects on acute
kidney injury (AKI) through paracrine/endocrine actions. If the protective effect is mediated in …

Mesenchymal stem cell (MSC) has been implied to have the therapeutic potential on chronic
kidney disease (CKD). However, the underlying mechanism is still unclear and …

Severe acute renal failure (ARF) remains a common, largely treatment-resistant clinical
problem with disturbingly high mortality rates. Therefore, we tested whether administration of …

In solid organ transplantation, mesenchymal stem cell (MSC) therapy is strongly emerging
among other cell therapies due to the positive results obtained in vitro and in vivo as an …

Chronic renal failure is an important clinical problem with significant socioeconomic impact
worldwide. Despite advances in renal replacement therapies and organ transplantation …

PURPOSE: The potential use of stem cells for acute and chronic renal injury is under
intensive investigation. We summarized the current literature on the potential therapeutic …